Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 17;5(24):e144079.
doi: 10.1172/jci.insight.144079.

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans

Affiliations

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans

Jan Borén et al. JCI Insight. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic lipid accumulation. The transmembrane 6 superfamily member 2 (TM6SF2) E167K genetic variant associates with NAFLD and with reduced plasma triglyceride levels in humans. However, the molecular mechanisms underlying these associations remain unclear. We hypothesized that TM6SF2 E167K affects hepatic very low-density lipoprotein (VLDL) secretion and studied the kinetics of apolipoprotein B100 (apoB100) and triglyceride metabolism in VLDL in homozygous subjects. In 10 homozygote TM6SF2 E167K carriers and 10 matched controls, we employed stable-isotope tracer and compartmental modeling techniques to determine apoB100 and triglyceride kinetics in the 2 major VLDL subfractions: large triglyceride-rich VLDL1 and smaller, less triglyceride-rich VLDL2. VLDL1-apoB100 production was markedly reduced in homozygote TM6SF2 E167K carriers compared with controls. Likewise, VLDL1-triglyceride production was 35% lower in the TM6SF2 E167K carriers. In contrast, the direct production rates for VLDL2-apoB100 and triglyceride were not different between carriers and controls. In conclusion, the TM6SF2 E167K genetic variant was linked to a specific reduction in hepatic secretion of large triglyceride-rich VLDL1. The impaired secretion of VLDL1 explains the reduced plasma triglyceride concentration and provides a basis for understanding the lower risk of cardiovascular disease associated with the TM6SF2 E167K genetic variant.

Keywords: Hepatology; Lipoproteins; Metabolism.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1. Decrease in the relative abundance (analyzed as mol%) of longer and more unsaturated fatty acids in VLDL1 and VLDL2 TGs in homozygous carriers of the TM6SF2 E167K genetic variant.
Lipids were extracted from VLDL1 and VLDL2, and the number of double bonds in fatty acids (i.e., degree of unsaturation) in TGs containing 48 to 58 carbon molecules was determined. The colors indicate the ratio of the individual lipid species in carriers of the TM6SF2 E167K genetic variant (n = 10) versus controls (n = 10). A linear mixed model with number of double bonds as fixed effect and subject as random effect was used to test for a linear effect of the number of double bonds, within fixed chain lengths. Data were normalized to mean of control group; P values correspond to tests of the linear effect of double bonds differing from 0. *P < 0.05.

References

    1. Cotter TG, et al. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864. doi: 10.1053/j.gastro.2020.01.052. - DOI - PubMed
    1. Matteoni CA, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413–1419. doi: 10.1016/S0016-5085(99)70506-8. - DOI - PubMed
    1. Arab JP, et al. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321–350. doi: 10.1146/annurev-pathol-020117-043617. - DOI - PubMed
    1. Brouwers M, et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia. 2020;63(2):253–260. doi: 10.1007/s00125-019-05024-3. - DOI - PMC - PubMed
    1. Romeo S, et al. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab. 2020;31(1):35–45. doi: 10.1016/j.cmet.2019.12.002. - DOI - PubMed

Publication types

MeSH terms